补体系统-药物开发和临床研究热点

补体系统是由35种广泛存在于血清、组织液和细胞膜具有酶活性的蛋白质组成的反应系统。补体激活有三种途径：1)经典途径2）旁路途径3）凝集素反应/MBL途径。补体系统可通过这3条既相对独立又相互联系的途径被激活，从而发挥调理吞噬、裂解细胞、介导炎症、免疫调节和清除免疫复合物等多种生物学效应，包括增强吞噬作用，增强吞噬细胞的趋化性；增加血管的通透性；中和病毒；细胞溶解作用；免疫反应的调节作用等。补体系统在抗感染和自身免疫及其他疾病的发展过程中发挥重要作用。

Euro Diagnostica补体功能检测试剂盒优势

1)ELISA检测方法-三种激活途径，相同的检测程序。

2)2005年上市，稳定的检测系统。

3）反映真实的体内补体水平。

4）3小时内出结果，快速、准确。

5）灵活性强-可以适应个性的化操作流程。

6）适合自动化检测系统检测（Dynex, DS2,DSX）

7) 与溶血试验（CH50, APH50）检测结果一致。

8）性能稳定，文献引用广

9）CE认证，可同时用于临床和科研检测。

Euro Diagnostica试剂盒应用实例:

1）药物开发-补体靶向治疗

研究表明,炎性疾病的发生、发展同补体的活化有关。因此,如何干扰和抑制补体活化产生的有害作用,成为药理学研究的焦点之一，Euro Diagnostica试剂盒用于评估补体靶向治疗效果（参考文献4-8）。

2）临床研究-补体功能/活性监测

补体功能的评估在补体相关疾病的发生和治疗中具有重要意义。文献5-9 用Euro Diagnostica试剂盒监测补体疾病治疗中补体水平。

3）补体脱靶反应

在某些情况下，补体激活可引起严重反应，比如候选药物的脱靶反应，抗体依赖的补体激活，移植排斥反应。（（参考文献12-13）。）

订购信息

订购信息

货号	产品名称	规格
COMPL300	Complement system Screen WIESLAB®	96T
COMPLCP310	Complement system Classical Pathway WIESLAB®	96T
COMPLMP320	Complement system MBL pathway WIESLAB®	96T
COMPLAP330	Complement system Alternative Pathway WIESLAB®	96T

1.Ricklin D and Lambris JD. Complement in Immune and Inflammatory Disorders:Therapeutic Interventions. J Immunol 2013; 190: 3839-3847应用文献：

2. Seelen MA et al. Functional analysis of the classical, alternative, and MBL pathways of

the complement system: standardization and validation of a simple ELISA. J Immunol Meth 2005; 296: 187–198

3. Salvesen B and Mollnes TE. Pathway-specific complement activity in pigs evaluated with a human functional complement assay. Mol Imm 2009;6:1620-1625

4.Hill A et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results. Abstract 2413 ;58th ASH Annual Meeting 2015

5. Jore MM et al. Structural basis for therapeutic inhibition of complement C5. Nature Structural & Molecular Biology 2016: doi:10.1038/nsmb.3196

6. Würzner R et al. Assessment of complement activity by ELISA. Abstract #41 16th Biennial Meeting of the European Society for Immunodeficiencies, ESID 2014

7. Kocsis A. Selective Inhibition of the Lectin Pathway of Complement with

Phage Display Selected Peptides against Mannose-Binding Lectin-Associated Serine

Protease (MASP)-1 and -2: Significant Contribution of MASP-1 to Lectin Pathway

Activation. J of Immunol 2010;185: 4169–4178

8. Kadam A P and Sahu A Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2. J of Immunol 2010;184: 7116-24

9. Volokhina E B et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015; 160: 237–43

10. Heinen S et al. Monitoring and modeling treatment of atypical hemolytic uremic

syndrome. Molecular Immunology 2013; 54:84– 88

11. Hallenstensen RF et al. Eculizumab treatment during pregnancy does not affect the

complement system activity of the newborn. Immunobiology 2015; 220:452–459

12. Castellano G et al. Therapeutic Targeting of Classical and Lectin Pathways of Complement Protects from Ischemia-Reperfusion- Induced Renal Damage. Am J Pathol 2010; 176:1648–1659

13. Brennan FR et al. Safety and immunotoxicity assessment of immunomodulatory

monoclonal antibodies. mAbs 2010; 2:3, 233-255

14. Mitsuru Sugimoto,etal.Possible participation of IgG4 in the activation of complement in IgG4-related disease with  hypocomplementemia.Modern Rheumatology,Volume 26, 2016 - Issue 2

15．Y. Palarasah,etal.Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system.Clincal&Experimental Immunology,Volume164, Issue3,June 2011,Pages 388-395.


联系电话 肖先生 手机：18611095289 （同微信） QQ 1985563437